Printer Friendly

Browse Lymphomas topic

Care and treatment subtopic

 

Articles

1-300 out of 382 article(s) nextnext page
Title Author Type Date Words
Five Gaza cancer patients died while awaiting referral outside the Strip, says WHO. Sep 28, 2017 242
NICE changes guidance for Takeda's non-Hodgkin's lymphoma drug. Aug 25, 2017 228
NICE changes guidance for Takeda's non-Hodgkin's lymphoma drug. Aug 25, 2017 232
Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung cancer patients. Jul 25, 2017 762
Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung cancer patients. Jul 25, 2017 780
The European Commission approves Novartis' Zykadi for lung cancer. Jul 3, 2017 164
The European Commission approves Novartis' Zykadi for lung cancer. Jul 3, 2017 160
B-lymphoblastic lymphoma of the rectum. Unnikrishnan, Puthillathu; Narayanan, Geetha; Kumar, Bhavya S.; Devi, Nandini Clinical report Jul 1, 2017 1216
EC approves first-line use of Novartis' Zykadia in ALK-positive advanced non-small cell lung cancer. Jun 29, 2017 231
Cancer battle may stop me from having another baby; 2fm's Louise admits she wants 2nd child but might not be able to conceive. Jun 27, 2017 538
European Hematology Association: Early Metabolic Response Determination by FDG-PET Allows Substantial Reduction of Chemotherapy and its Toxicity in Patients with Advanced Stage Hodgkin Lymphoma: the GHSG HD18 Study. Jun 24, 2017 454
European Hematology Association: Early Metabolic Response Determination by FDG-PET Allows Substantial Reduction of Chemotherapy and its Toxicity in Patients with Advanced Stage Hodgkin Lymphoma: the GHSG HD18 Study. Jun 24, 2017 460
Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease. Jun 5, 2017 2967
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma. May 31, 2017 1197
Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care. May 18, 2017 2706
United States : IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). May 15, 2017 555
IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). May 14, 2017 4845
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma. May 8, 2017 222
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma. May 8, 2017 218
Pfizer receives FDA Breakthrough Therapy designation for Lorlatinib. May 1, 2017 249
Pfizer receives FDA Breakthrough Therapy designation for Lorlatinib. May 1, 2017 245
Sonographic Assessment of the Terminal Thoracic Duct in Patients with Lymphedema. Gao, Chao; Yang, Meng; Su, Na; Li, Xiong-Wei; Yang, E-Lan; Huang, Jiu-Zuo; Yu, Nan-Ze; Long, Xiao Report May 1, 2017 2357
Graft-Versus-Host disease prevented after stem cell transplants. Apr 24, 2017 445
United States : Phase III ALUR study supports the use of Roches Alecensa for people with advanced ALK-positive lung cancer. Apr 4, 2017 332
Asian-variant intravascular large B-cell lymphoma. Su, Derrick W.; Pasch, Whitney; Costales, Cristina; Siddiqi, Imran; Mohrbacher, Ann Clinical report Apr 1, 2017 2761
Nice rejects Opdivo for classical Hodgkin lymphoma. Mar 15, 2017 253
Nice rejects Opdivo for classical Hodgkin lymphoma. Mar 15, 2017 249
SMC recommends Roche's Gazyvaro, rejects Shire's Onivyde. Mar 14, 2017 281
SMC recommends Roche's Gazyvaro, rejects Shire's Onivyde. Mar 14, 2017 285
Radiation therapy of periorbital lymphoma in a blue-and-gold macaw (Ara ararauna). Alexander, Amy B.; Griffin, Lynn; Johnston, Matthew S. Report Mar 1, 2017 4361
Novartis drug Zykadia granted FDA Priority Review. Feb 24, 2017 256
Novartis drug Zykadia granted FDA Priority Review. Feb 24, 2017 252
Acute kidney injury secondary to lymphoma. Dhillon, Patwant; Battistella, Marisa Report Jan 1, 2017 2359
Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. Wang, Qin; Qin, Yan; Kang, Su-Yi; He, Xiao-Hui; Liu, Peng; Yang, Sheng; Zhou, Sheng-Yu; Zhang, Chang Report Dec 5, 2016 4194
Merck's sBLA for KEYTRUDA to be reviewed by US FDA for treating patients with refractory classical Hodgkin lymphoma. Dec 2, 2016 321
Merck's sBLA for KEYTRUDA to be reviewed by US FDA for treating patients with refractory classical Hodgkin lymphoma. Dec 2, 2016 317
Neither 10-nor 14-day sequential treatment is better than standard triple therapy for helicobacter pylori eradication. Warrington, Emanuel; Lopez-Roman, Orlando; Tirado-Montijo, Rafael; Urbina, Rafael; Cruz-Correa, Marc Report Dec 1, 2016 3736
Switzerland : Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer. Nov 17, 2016 589
Treatments Commence Using UAE's First Varian TrueBeam(TM) System. Nov 14, 2016 631
Treatments Commence Using UAE's First Varian TrueBeam(TM) System. Nov 14, 2016 670
Ex-Blackpool ace Armfield, 81, in 2nd cancer fight. Nov 5, 2016 192
Ex-England ace Armfield, 81, in 2nd cancer fight. Nov 5, 2016 192
November is National Pet Cancer Awareness Month. Nov 1, 2016 1160
United States : Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedo. Oct 15, 2016 282
Cancer trends shifting in HIV-positive patients. Jancin, Bruce Oct 15, 2016 673
The Leukemia & Lymphoma Society Introduces Random Acts of Light To Help Bring Moments of Light To Darkness of Cancer. Oct 6, 2016 833
Magnetic Resonance Imaging Features of Extraocular Muscle Lymphoma in Five Cases. Guo, Peng-De; Xian, Jun-Fang; Man, Feng-Yuan; Liu, Zhao-Hui; Yan, Fei; Zhao, Jing; Wang, Zhen-Chang Report Oct 5, 2016 1138
Cancer trends shifting in HIV-positive patients. Jancin, Bruce Oct 1, 2016 598
AbbVie submits sNDA for ibrutinib (IMBRUVICA) for treating marginal zone lymphoma. Sep 27, 2016 290
AbbVie submits sNDA for ibrutinib (IMBRUVICA) for treating marginal zone lymphoma. Sep 27, 2016 286
Takeda Pharmaceutical Co.'s ADCETRIS (brentuximab vedotin) was approved by the European Commission for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT). Sep 1, 2016 149
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 256
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 252
NEW THERAPY EXTENDS CANCER PATIENTS' LIVES; Leukaemia drug trial 'offers hope'. Aug 11, 2016 310
Cancer drugs get Scottish approval. Aug 9, 2016 134
Singapore : Singapore scientists discover new pathways leading to cancer progression. Jul 19, 2016 835
United States : Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma. Jul 8, 2016 472
Japan,United States : Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma. Jul 8, 2016 472
Takeda obtains EC approval of ADCETRIS for consolidation treatment in post-transplant Hodgkin lymphoma. Jul 7, 2016 239
Takeda obtains EC approval of ADCETRIS for consolidation treatment in post-transplant Hodgkin lymphoma. Jul 7, 2016 235
WIG MATES! School pals get behind fight for brave cancer boy Alex. Jun 19, 2016 257
Autologous Stem Cell Transplantation Offers Safe and Effective--and Potentially Curative - Option for Patients with HIV-Associated Lymphoma. Jun 13, 2016 1318
Merck's KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL), has been granted Breakthrough Therapy Designation by the FDA. Jun 1, 2016 115
Japan : Takeda receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma. May 28, 2016 498
Japan,United States : Takeda Receives Positive CHMP Opinion for ADCETRIS(brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma. May 28, 2016 498
Primary Central Nervous System Lymphoma. Dong, Yan-Hong; Teng, Zhen-Jie; Hu, Ming; Wei, Ci; Chen, Ying-Min; Zhao, Huan-Fen; Zhang, Shu-Qian; Report May 1, 2016 1444
Sweden : CHMP recommends EU approval of Roches Gazyvaro for people with previously treated follicular lymphoma. Apr 30, 2016 242
Ibrutinib is a new standard treatment. Martin, Peter Apr 1, 2016 197
Orbital apex syndrome caused by aspergilloma in an immunocompromised patient with cutaneous lymphoma: a case report of a rare entity. Cheko, A.; Jung, S.; Teuber-Hanselmann, S.; Oseni, A.W.; Tsogkas, A.; Scholz, M.; Petridis, A.K. Report Apr 1, 2016 1116
'Cancer patient meets man who helped to save his life'. Mar 31, 2016 671
Cancer patient gets to meet life-saving donor. Mar 31, 2016 641
United States : XALKORI Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. Mar 14, 2016 514
A glimpse into future of cancer care in the city; NHS BOSSES SUBMIT PLANS FOR NEW 11-STOREY HOSPITAL. Mar 2, 2016 371
Bilateral facial paralysis in a patient with B-cell low grade lymphoma and its rehabilitation/Dusuk gradli B hucreli lenfomali bir hastada iki tarafli fasiyal paralizi ve rehabilitasyonu. Benlidayi, Ilke Coskun; Aytan, Pelin; Gokcen, Neslihan; Basaran, Sibel; Gurkan, Emel; Guzel, Rengin Report Mar 1, 2016 1658
The war against a killer disease. Feb 14, 2016 153
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy. Jan 28, 2016 1391
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy. Jan 28, 2016 1429
Japan : European Commission Approves Label Variation for ADCETRIS (Brentuximab Vedotin) to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anapl. Jan 23, 2016 404
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Jan 20, 2016 1187
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Jan 20, 2016 1225
Therapy-related T/myeloid mixed phenotype acute leukemia in a patient treated with chemotherapy for cutaneous diffuse large B cell lymphoma. Roberts, Evans, III; Oncale, Melody; Safah, Hana; Schmieg, John Clinical report Jan 1, 2016 1911
United States : Combination Ibrutinib (IMBRUVICA) Demonstrates a Strong Response Rate in Treatment-Naive Patients with Follicular Lymphoma. Dec 8, 2015 638
IMBRUVICA (ibrutinib) Phase 3 RAY Data Show Significant Improvements in Progression-Free Survival Versus Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Dec 7, 2015 2826
Ibrutinib Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Leukaemia, Lymphoma, Study Finds. Dec 7, 2015 491
Ibrutinib Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Leukaemia, Lymphoma, Study Finds. Dec 7, 2015 461
IMBRUVICA (ibrutinib) Phase 2 RESONATE-17 Data Show Robust Clinical Activity and Promising Survival Outcomes in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia with del 17p. Dec 7, 2015 2690
Cancer survivor set to tie the knot. Dec 6, 2015 203
Ibrutinib (IMBRUVICA) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Dec 6, 2015 2947
Lymphoma without Lymphadenopathy. Jain, Ashutosh; Kumar, Nilesh; Jangid, Mahendra; Gambhir, Indrajeet; Tilak, Vijai Case study Dec 5, 2015 904
November is National Pet Cancer Awareness Month. Nov 3, 2015 1053
A single-centre experience with tumour tract seeding associated with needle manipulation of renal cell carcinomas. Viswanathan, Aravind; Ingimarsson, Johann P.; Seigne, John D.; Schned, Alan R. Case study Nov 1, 2015 1823
myTomorrows Announces an Agreement With Spectrum for an Early Access Program for Pralatrexate Injection for Patients With Peripheral T-Cell Lymphoma (PTCL). Oct 19, 2015 711
Primary testicular lymphoma with solitary cutaneous nodule as the initial presentation. Dalal, Varsha; Kaur, Manveen; Siraj, Fouzia; Singh, Avninder; Bansal, Anju Report Oct 1, 2015 1863
The next step in treatment: Personalized medicine. Oct 1, 2015 145
Disseminated enteroviral infection associated with obinutuzumab. Dendle, Claire; Gilbertson, Michael; Korman, Tony M.; Golder, Vera; Morand, Eric; Opat, Stephen Report Sep 1, 2015 1829
The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-[kappa]B-driven tumour intravasation. Unger, Christine; Kiss, Izabella; Vasas, Andrea; Lajter, Ildiko; Kramer, Nina; Atanasov, Atanas Geor Report Aug 15, 2015 6635
Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint. Aug 12, 2015 1385
Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion Meets Primary Endpoint. Aug 12, 2015 1421
CASI Pharmaceuticals Announces Availabilty Of Anti-Cancer Drug ZEVALIN In Hong Kong For Non-Hodgkin's Lymphoma. Jul 20, 2015 1529
Janssen's IMBRUVICA,u- (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Jul 10, 2015 2720
CORRECTION - Janssen-Cilag International NV: Janssen's IMBRUVICA,u- (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Correction notice Jul 10, 2015 2782
Appirio Provides Technology Support to The Leukemia & Lymphoma Society (LLS) to Help Blood Cancer Patients Live Better, Longer Lives. Jun 29, 2015 1040
DEP LEPPARD STAR VIV: MY CANCER'S BACK; Guitarist quits tour for treatment. Jun 21, 2015 265
Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Jun 12, 2015 1385
Ibrutinib (IMBRUVICA) Improved Survival for Treatment-Naive Chronic Lymphocytic Leukemia Patients in Phase III RESONATE(TM)-2 Trial. Clinical report Jun 4, 2015 1456
Ibrutinib (IMBRUVICA,u-) HELIOS Interim Analysis Data Show Significant Reductions in Risk of Progression or Death in Patients With Previously-Treated Chronic Lymphocytic Leukaemia. May 30, 2015 2995
Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA (Ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia. May 22, 2015 2325
Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation. May 6, 2015 1208
Langerhans cell histiocytosis followed by Hodgkin lymphoma: a case report. Safaei, Akbar; Bagheri, Mandana; Shahryari, Jahanbanoo; Noori, Sadat; Esmailzade, Elmira Report May 1, 2015 1689
Angiocentric NK/T cell lymphoma of the nose. Chellathurai, Sreenivas; Velayudham, Prabhu; Balasubramanian, K. Clinical report Apr 23, 2015 991
IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL). Apr 20, 2015 2512
Drug 'stops body battling treatment' Aid for immune system in the fight against blood cancer. Apr 14, 2015 470
Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Mar 16, 2015 2188
Phase 3 Study with IMBRUVICA (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression. Mar 16, 2015 2042
The Leukemia & Lymphoma Society Applauds Therapy Advances for Myeloma Patients. Feb 26, 2015 817
Blog is best therapy for surgeon in cancer battle. Feb 19, 2015 639
Switzerland : Roche's Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin's lymphoma. Feb 5, 2015 423
The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Patients with Waldenstrom's Macroglobulinemia. Jan 30, 2015 606
The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Patients with Waldenstrom's Macroglobulinemia. Jan 29, 2015 604
United Kingdom : Innovative cancer research project secures Au30 million investment. Jan 23, 2015 416
Molecular monitoring for minimal residual disease. Brunstein, John Jan 1, 2015 1932
IMBRUVICA (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy. Dec 9, 2014 2761
Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL). Dec 9, 2014 3732
United Kingdom : Southampton scientists make breakthrough in understanding of rare blood cancer. Dec 9, 2014 359
US/Global Policymakers Urged to Accelerate Cancer Research, Biomedical Discovery. Dec 8, 2014 1330
IMBRUVICA (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy. Dec 8, 2014 2761
Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL). Dec 8, 2014 3732
IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival in Patients with High-Risk Chronic Lymphocytic Leukemia with Genetic Mutation. Dec 8, 2014 2973
Application Submitted to the EMA to Expand the Therapeutic Indication for IMBRUVICA (ibrutinib) to Include Treatment of Waldenstrom's Macroglobulinemia. Dec 1, 2014 2174
Cervical presentation of peripheral T-cell lymphoma not otherwise specified. Misono, Alexander S.; Lin, Harrison W.; Lee, Linda N.; Ferry, Judith A.; Rocco, James W. Brief article Dec 1, 2014 113
November Marks National Pet Cancer Awareness Month. Nov 5, 2014 1221
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia. Oct 23, 2014 913
NeoGenomics introduces molecular testing for resistance to BTK inhibitors for chronic lymphocytic leukaemia. Oct 23, 2014 431
European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer. Oct 17, 2014 3143
European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer. Oct 17, 2014 3142
An intravascular lymphoma with extravascular tendencies. Thomas, Cody A.; Guileyardo, Joseph M.; Krause, John R. Case study Oct 1, 2014 1464
Necrotizing histiocytic lymphadenitis/Kikuchi-Fujimoto disease: a case report and review of literature. Gubbala, Srinivas; Satyanarayana, V. Case study Sep 29, 2014 1180
Cancer Genetics, Beth Israel Deaconess Medical Center to study genomic biomarkers in DLBCL patients. Sep 23, 2014 528
Lymphoma third most common type of disease in children: expert. Sep 21, 2014 392
Hope-and help-for cancer patients. Sep 21, 2014 586
Waldeyer ring lymphoma: a case series. Teh, Carren S.L.; Jayalakshmi, Pailoor; Chong, Sheldon Y.C. Brief article Sep 1, 2014 148
An unusual case of primary bilateral renal lymphoma: a case report. Bora, Mitul; Das, Sadhan Brata; Loitongbam, Roslin; Barthkur, Himadri Sekhar; Biswas, Tandra Clinical report Aug 21, 2014 1974
Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical Program in Patients with AML, MDS and other Blood Cancers. Clinical report Jul 28, 2014 702
Belgium : Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA for use in the Treatment of Two Forms of Blood Cancer. Jul 26, 2014 425
The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers. Jul 23, 2014 505
Switzerland : Japan becomes first country to approve Roche s alectinib for people with a specific form of advanced lung cancer. Jul 4, 2014 359
Marginal zone B-cell lymphoma of the lacrimal gland secondary to Sjogren's syndrome/Sjogren sendromuna ikincil gelisen lakrimal glandin marjinal zon b hucreli lenfomasi. Ilhan, Hatice Deniz; Turkoglu, Elif Betul; Bilgin, Ahmet Burak; Akkaya, Bahar; Unal, Mustafa Clinical report Jul 1, 2014 1320
Curis re-opens patient dosing of CUDC-427 monotherapy study for treating advanced and/or refractory solid tumors or lymphomas patients. Jun 6, 2014 215
Curis re-opens patient dosing of CUDC-427 monotherapy study for treating advanced and/or refractory solid tumors or lymphomas patients. Jun 6, 2014 211
Vitamin D levels linked to survival rates among cancer patients: strongest correlation found with breast cancer, lymphoma and colorectal cancer survival. Jun 1, 2014 280
Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma Compared to ofatumumab. May 31, 2014 2557
Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. May 31, 2014 2795
Ibrutinib (IMBRUVICA) RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. May 31, 2014 3425
IMBRUVICA (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study. May 31, 2014 3275
IMBRUVICA (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL. May 31, 2014 2586
Author Beats the Odds: Cured from Stage 4 Cancer with God's Word. May 15, 2014 464
PS1m for uni's cancer project. May 15, 2014 105
45,000 Cancer Patients Have Been Flown To Their Life Saving Treatment Centers. May 2, 2014 394
Author Beats the Odds: Cured from Stage 4 Cancer with God's Word. Apr 29, 2014 464
Japan : "ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Av. Apr 18, 2014 220
United States : Novartis study published in NEJM showed LDK378 demonstrated an overall response rate of 58% in patients with ALK+ NSCLC. Mar 27, 2014 370
WONDER DRUG KILLED OFF MY 70 TUMOURS IN 2 WEEKS; Cancer patient's miracle 'cure'. Feb 26, 2014 468
WONDER DRUG KILLED OFF MY 70 TUMOURS IN 2 WEEKS; Cancer patient's miracle 'cure'. Feb 26, 2014 458
The Leukemia & Lymphoma Society Applauds FDA's Approval of Ibrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia. Feb 12, 2014 657
Primary testicular diffuse large B-cell lymphoma of the non-germinal centre type--case report with a note on imprint. cytology. M.B., Lekha; Shetty, Archana; V., Geethalmani; C., Vijaya; Rehan, Mudasser Clinical report Feb 3, 2014 1348
Immunosuppressives' benefits outweigh risks in IBD. McKnight, Whitney Feb 1, 2014 606
Gilead's Idelalisib NDA accepted by US FDA for the treatment of refractory indolent non-Hodgkin's lymphoma. Jan 14, 2014 210
Gilead's Idelalisib NDA accepted by US FDA for the treatment of refractory indolent non-Hodgkin's lymphoma. Jan 14, 2014 206
Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis. Clinical report Jan 7, 2014 1739
Mucosa-associated lymphoid tissue lymphoma arising from the kidney. Niwa, Naoya; Tanaka, Nobuyuki; Horinaga, Minoru; Hongo, Hiroshi; Ito, Yujiro; Watanabe, Takuro; Masu Author abstract Jan 1, 2014 1531
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65. Dec 9, 2013 2677
Endovascular therapy for acute tumour-related obstruction of the superior vena cava using a self-expanding Nitinol stent. Kamusella, P.; Wissgott, C.; Andresen, R. Report Dec 1, 2013 3728
MicroRNA involvement in human cancers. Yanaihara, Nozomu; Harris, Curtis C. Dec 1, 2013 1145
Early stem cell transplants for non-Hodgkin's lymphoma. Stiff, Patrick Nov 11, 2013 648
The Leukemia & Lymphoma Society Applauds FDA's Approval of Gazyva as First-Line Treatment for Patients with Chronic Lymphocytic Leukemia. Nov 4, 2013 512
Differentiation of thyroid malignancies--an ultrasonographic criteria. Pratap, Vijai; Jain, S.K. Clinical report Nov 4, 2013 2390
United States : MOLECULAR TEMPLATES gets $8.5M for cancer drug. Oct 11, 2013 140
Japan : New Drug Application Filed for ALK Inhibitor Alectinib Hydrochloride for the Treatment of ALK Fusion Gene Positive Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer. Oct 9, 2013 415
Ventana receives approval from China's FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients. Sep 11, 2013 1056
Ventana receives approval from China's FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients. Sep 11, 2013 1061
Do your bit in cancer fight; Views of the North 30/08/13. Aug 30, 2013 254
Clinicopathological study of diseases homing and infiltrating bone marrow in children less than 3 years of age. Ramani, M.; Ranganath, D.; Geetha, K.; Husain, Kazi Wajid; Kiran, Khyati J.; Deshmukh, Puja Clinical report Aug 26, 2013 1983
New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of Two B-Cell Malignancies. Jul 10, 2013 1527
Therapeutic management of cutaneous lymphoma in a dog. Kshama, M.A.; Yathiraj, S.; Rao, Suguna Report Jul 1, 2013 807
Ibrutinib Data Published in The New England Journal of Medicine Show 68 Percent Overall Response Rate in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL). Jun 19, 2013 1659
Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma. Jun 16, 2013 1767
Cancer patient Paul plans inspiring night; Musician's 'thanks' to hospital ward. Jun 8, 2013 504
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer. Jun 3, 2013 1778
Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer. Jun 3, 2013 1412
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK Tyrosine Kinase Inhibitors: guideline from the College Of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Lindeman, Neal I.; Cagle, Philip T.; Beasley, Mary Beth; Chitale, Dhananjay Arun; Dacic, Sanja; Giac Report Jun 1, 2013 34390
Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma. May 6, 2013 1066
Senesco Technologies Inc concludes Cohort 2 of Phase 1b/2a trial with multiple myeloma or diffuse large B-cell lymphoma patients. Apr 23, 2013 246
Senesco Technologies Inc concludes Cohort 2 of Phase 1b/2a trial with multiple myeloma or diffuse large B-cell lymphoma patients. Apr 23, 2013 242
NIH trial shows promising results in treating a lymphoma in young people. Apr 11, 2013 138
Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Naderi, Nadia; Yang, David T. Disease/Disorder overview Apr 1, 2013 4000
Lymphoma in the breast. Ha, Kelli Y.; Wang, Jean C.; Gill, Javed I. Apr 1, 2013 1226
Support for cancer sufferers. Mar 25, 2013 202
Switzerland : Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer. Mar 15, 2013 416
Hugo Chavez One Of Several Latin Leaders Struck By Cancer In Recent Years. Mar 6, 2013 434
Sequenta Launches ClonoSIGHT, First Sequencing-Based Minimal Residual Disease Test for Leukemia and Lymphoma. Feb 13, 2013 476
Childhood cancer in Cote d'Ivoire, 1995-2004 - challenges and hopes. Yao, J.J.A.; Couitchere, L.; Atimere, Y.; Kone, D.; Azagoh-Kouadio, R.; Oulai, M.S.; Stefan, D.C. Report Feb 1, 2013 2729
Secondary lymphoma of the parotid gland: clinical experience. Williams-Smith, Lorraine; Gupta, Reena; Osborne, Ryan F. Case study Feb 1, 2013 417
80% of young people now beat this cancer. Jan 10, 2013 124
Misdiagnosis of tuberculosis in patients with lymphoma. Puvaneswaran, B.; Shoba, B. Report Jan 1, 2013 1397
Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Krause, John R.; Drinkard, Lee C.; Keglovits, Latoya C. Case study Jan 1, 2013 1456
Anaplastic large cell lymphoma in the setting of textured breast implant: a call for patients and physicians education. Zakhary, Joseph M.; Jahromi, Alireza Hamidian; Chaudhery, Subnum; Kim, Mary Clinical report Jan 1, 2013 1588
Laparoendoscopic single-site ovariectomy: an indication of choice for ovarian cryopreservation. Dorez, Maxence; Delotte, Jerome; Thibault, Emmanuelle; Ciuca, Stefan; Mounier, Nicolas; Bongaina, An Case study Jan 1, 2013 1207
Study ties drug shortage to poorer cancer survival. Clinical report Dec 27, 2012 499
Drug shortage linked to greater risk of relapse in young Hodgkin lymphoma patients. Dec 26, 2012 1490
Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer. Dec 11, 2012 1470
Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients. Dec 11, 2012 1268
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. Dec 10, 2012 2212
Test-retest reliability of the aerobic power index submaximal exercise test in cancer patients. Furzer, Bonnie J.; Wallman, Karen E.; Ackland, Timothy R.; Joske, David J.L. Report Dec 1, 2012 4057
Primary cutaneous CD30-positive anaplastic large-cell lymphoma of the external auditory canal. Marcal, Nuno; Campelos, Sofia; Dias, Luis; Goncalves, Matos; Pereira, Gabriel; Godinho, Tiago Brief article Dec 1, 2012 131
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy. Oct 24, 2012 827
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy. Oct 24, 2012 831
Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS[R] as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over. Oct 17, 2012 1576
Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS[R] for Post-Transplant Patients with Hodgkin Lymphoma. Sep 25, 2012 1725
Biovest Conducts Meeting with EMA Advancing Process to Seek EU Approval for Cancer Vaccine. Sep 20, 2012 1011
Cell Therapeutics Announces European Launch of Pixuvri(R) for Treatment of Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma. Sep 11, 2012 1808
Cell Therapeutics Announces European Launch Of Pixuvri For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma. Sep 11, 2012 1757
Scientist's childhood cancer cash; Grant to research better treatment. Aug 15, 2012 477
Spectrum Pharmaceuticals Announces Publication in the Journal of Clinical Oncology of Encouraging ZEVALIN Data in Patients with Mantle-Cell Lymphoma. Aug 2, 2012 1299
Japan,United States : Takeda and Millennium Announce Positive CHMP Opinion for Conditional Approval of ADCETRISA (brentuximab vedotin) in Europe. Jul 24, 2012 417
Seattle Genetics Announces ADCETRIS[R] Receives Positive CHMP Opinion for Conditional Approval in European Union. Jul 20, 2012 833
Millennium and Takeda Announce Positive CHMP Opinion for Conditional Approval of ADCETRIS[R] (brentuximab vedotin) in Europe. Jul 20, 2012 965
Biovest's BiovaxID[R] Lymphoma Vaccine Featured in FierceBiotech Cancer Immunotherapy Special Report. Jul 18, 2012 948
Primary solitary extramedullary plasmacytoma of the tongue. Onal, Cem; Oymak, Ezgi; Uguz, Aysun; Ergin, Melek Case study Jul 1, 2012 2295
NEUTRROPHIL TOXICITY AND PRIMARY PROPHYLAXIS IN DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP. Naqi, Naeem; Khattak, Javaid Report Jun 30, 2012 1747
Biovest Initiates Formal Regulatory Approval Process for BiovaxID[R] Cancer Vaccine in Europe. Jun 20, 2012 1064
Seattle Genetics Highlights Updated Survival Data from ADCETRIS[R] Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma. Jun 14, 2012 1841
Spectrum Pharmaceuticals Announces Promising Clinical Data for ZEVALIN[R] and Belinostat at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. Jun 5, 2012 1950
Onyx Pharmaceuticals and the University of Texas MD Anderson Cancer Center Announce Strategic Alliance in Multiple Myeloma and Lymphoma. Jun 4, 2012 949
New compound 'may prove to be successful for lung cancer patients'. Jun 3, 2012 371
Malignant lymphoma of T-cell origin in a Humboldt penguin (Spheniscus humboldti) and a pink-backed pelican. Schmidt, Volker; Philipp, Hans-Christian; Thielebein, Jens; Troll, Susanne; Hebel, Christiana; Auppe Report Jun 1, 2012 2645
Biovest Interviewed by OneMedRadio; Discusses Key Milestones Expected to Establish BiovaxID[R] as the World's First Personalized Cancer Vaccine for the Treatment of Non-Hodgkin's Lymphoma. May 31, 2012 846
Data from Brentuximab Vedotin (SGN-35) Pivotal Phase II Trial in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Published in the Journal of Clinical Oncology. May 23, 2012 1239
Experts for maintaining nationwide data of blood cancer patients Say disease now curable. May 19, 2012 410
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN[R] in Combination with the Redox Modulating Agent Motexafin Gadolinium (MGd). May 17, 2012 1392
Cell Therapeutics' Pixuvri Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas. May 10, 2012 1682
Cell Therapeutics' Pixuvri Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas. May 10, 2012 1760
Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS[TM] in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma. May 7, 2012 1836
Primary NK/T-cell lymphoma of the larynx. Uri, Nechama; Schindler, Yaakov; Quitt, Miriam; Valkovsky, Olga; Barzilai, Geva Case study May 1, 2012 1246
Primary Brain T-Cell Lymphoma during Pregnancy. Ilker, Arikan; Aykut, Barut; Muge, Harma; Ibrahim, Harma Mehmet; Ulkua, Ozmen Bayar; Tugba, Duzcan; Report Apr 30, 2012 1267
Biovest Interviewed by OneMedRadio Regarding Global Regulatory Strategy to Seek Approvals for BiovaxID[R] Cancer Vaccine. Apr 19, 2012 1154
Seattle Genetics Announces Pivotal ADCETRIS[TM] (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical Oncology. Mar 26, 2012 1596
Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma. Mar 6, 2012 551
What is your diagnosis? Report Mar 1, 2012 2009
Effect of ginger on chemotherapy-induced nausea and/or vomiting in cancer patients. Alparslan, Guler Balci; Ozkarman, Ayse; Eskin, Nuran; Yilmaz, Songul; Akay, Meltem; Acikgoz, Ayfer; Report Mar 1, 2012 2924
Pharmacyclics/Janssen Biotech's PCI-32765 Has Earned Decision Resources' Proprietary Clinical Gold Standard Status for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma. Feb 16, 2012 719
Proteomic analysis of the molecular response of Raji cells to maslinic acid treatment. Yap, W.H.; Khoo, K.S.; Limb, S.H.; Yeo, C.C.; Lim, Y.M. Report Feb 15, 2012 6445
Change in treatment norms to top cancer conference agenda. Calendar Jan 25, 2012 402
Large cell lymphoma associated with prosthetic joint debris. Ong, Menchu G.; Ghali, G.E.; Veillon, Diana; Cotelingam, James Case study Jan 1, 2012 674
Southampton Varsity research reveals new ways to treat blood cancers. Dec 22, 2011 456
Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS[TM] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. Dec 13, 2011 2220
Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients. Dec 11, 2011 1394
Study Favors As-Needed Treatment Over Maintenance Therapy for Patients with Follicular Lymphoma. Clinical report Dec 11, 2011 1116
Therapy for feline lymphoma. Dec 1, 2011 230
Anaplastic Large Cell Lymphoma of Scrotal skin. Report Nov 30, 2011 2569
International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment. Nov 8, 2011 1003
Breast swelling and erythema in a teen: an ED doctor suspected a cat scratch was to blame and prescribed antibiotics. A week later, though, the patient developed dyspnea. Lester, Jeffrey L.; Buccolo, Larissa S.; McAdams, Christina A. Case study Nov 1, 2011 1353
Neck masses confined to the submental space: our experience with 24 cases. Ural, Ahmet; Imamoglu, Mehmet; Isik, Abdulcemal Umit; Bahadir, Osman; Bektas, Devrim; Cobanoglu, Ben Report Nov 1, 2011 2029
Two cases of durable regression of primary B-cell cutaneous lymphoma following mistletoe treatment alone. Orange, M.; Lace, A.; Fonseca, M.; Laue, H.B. von; Geider, S. Report Oct 15, 2011 388
Primary cutaneous large B-cell lymphoma, leg type. Thomas, Vibha; Dobson, Robin; Mennel, Robert Clinical report Oct 1, 2011 2636
Evaluation of cardiac functions by tissue Doppler echocardiography method in long-term follow-up of pediatric Hodgkin lymphoma patients. Bozkurt, Ceyhun; Orun, Utku Arman; Ertem, Ayse Ulya; Ocal, Burhan; Sahin, Gurses; Yuksek, Nazmiye; O Report Sep 1, 2011 4027
Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma. Aug 17, 2011 956
Emergent BioSolutions begins Phase Ib/II study of TRU-016 in lymphoma patients. Aug 17, 2011 240
Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies. Aug 17, 2011 1711
New technique promises to treat lymphoma with no major side effects. Aug 15, 2011 277
A fifteen-year review of lymphomas in a Nigerian tertiary healthcare centre. Oluwasola, A. Olayiwola; Olaniyi, John A.; Otegbayo, Jesse A.; Ogun, Gabriel O.; Akingbola, Titi S.; Report Aug 1, 2011 4310
The Gamida Cell-Teva Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx[R], a Cord Blood Stem Cell Product, for Leukemia and Lymphoma. Jul 12, 2011 601
Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma. Sinsabaugh, Christopher Report Jun 22, 2011 2711
Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL. Jun 16, 2011 1045
New Book Provides Hope and Encouragement for Cancer Patients. May 19, 2011 485
Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Priority Review for Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL. May 2, 2011 1118
Second US Clinical Study In HIV/AIDS Lymphoma Patients Using Benitec Limited (ASX:BLT) ddRNAi Technology. Mar 21, 2011 430
Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Mar 21, 2011 1297
US study in lymphoma HIV/AIDS patients uses Benitec's ddRNAi technology. Mar 21, 2011 215
FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial. Mar 10, 2011 1788
Study examines link between HIV and cancer in patients. Mar 10, 2011 168
Immunomodulators for atopy didn't up lymphoma risk. McNamara, Damian Mar 1, 2011 753
Biovest Secures Financing from State of Minnesota and City of Coon Rapids to Establish Manufacturing Site for Lymphoma Cancer Vaccine. Feb 24, 2011 1433
NIH scientists identify possible gene target for treating a form of lymphoma. Dec 22, 2010 178
Aethlon Medical Demonstrates Ability to Capture Colorectal and Lymphoma Cancer Exosomes. Dec 20, 2010 1724
Biovest Issues Post-ASH Update for BiovaxID[R] Personalized Cancer Vaccine including Significance of Isotype Phase III Data. Dec 20, 2010 4239
Novartis' LBH589 shows disease control, tumor reduction in pretreated Hodgkin lymphoma patients. Dec 7, 2010 267
Weekly VELCADE in Combination with Rituximab Improves Progression-Free Survival and Response Rate in Patients with Relapsed or Refractory Follicular Lymphoma. Clinical report Dec 7, 2010 2057
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients. Clinical report Dec 6, 2010 2326
New Standards of Care and Novel Treatment Options for Several Forms of Lymphoma Unveiled. Dec 5, 2010 2936
Novartis reports Phase II data show increase in disease control, tumor reduction in pretreated Hodgkin lymphoma patients. Dec 1, 2010 205
Febrile neutropenia in children with lymphoma and solid tumors: One center experience/ Lenfoma ve solid tumorlu cocuklarda febril notropeni: Tek merkez deneyimi. Demirkaya, Metin; Ozgur, Taner; Celebi, Solmaz; Sevinir, Betul; Hacimustafaoglu, Mustafa Report Dec 1, 2010 3945
New way to treat cancer; North medics hail research into disease. Nov 22, 2010 409
Epizyme Publication Identifies Novel Opportunity for Treatment of Genetically-Defined Human B-cell Lymphomas. Disease/Disorder overview Nov 15, 2010 538
Excellence honour for cancer efforts; The patients in Newcastle get best treatment. Sep 23, 2010 454
We're so lucky to be living in North; Mum's praise for hospital. Sep 23, 2010 465
CanSurvive marks World Lymphoma Awareness Day in Egypt. Disease/Disorder overview Sep 22, 2010 547
Praise for the cancer pioneers; Scientists' research into leukaemia is celebrated. Sep 22, 2010 456
Gamma secretase and Notch as therapeutic targets in cancer. Filipovic, Aleksandra; Giamas, Georgios; Coombes, R. Charles; Stebbing, Justin Sep 1, 2010 3141
HemaQuest commences Phase II study of HQK-1004 in EBV-related Mmalignancies. Aug 12, 2010 376
Study Analysis Identifies Potential Biomarkers of VELCADE (Bortezomib) Activity in Patients with Relapsed Mantle Cell Lymphoma. Jul 29, 2010 1285

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters